Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab versus methylprednisolone for active Graves' orbitopathy
2015-002127-26Phase 2Completed
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Graves' ophthalmopathy (TED) and Graves' disease comparing Benlysta with Solu-Medrol (2 arms). Primary endpoint: Clinical activity score response at 48 weeks. Started Mar 2019; status: completed.
02
Drugs
belimumabmethylprednisolone sodium succinate
03
Conditions
Graves' ophthalmopathy (TED)Graves' disease
Beyond the preview
Go deeper on 2015-002127-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002127-26.